Feinberg
Northwestern Medicine | Northwestern University | Faculty Profiles

News Center

  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Menu
  • Categories
    • Campus News
    • Disease Discoveries
    • Clinical Breakthroughs
    • Education News
    • Scientific Advances
  • Press Release
  • Media Coverage
  • Podcasts
  • Editor’s Picks
    • COVID-19
    • Cardiology
    • Cancer
    • Neurology and Neuroscience
    • Aging and Longevity
    • Artificial Intelligence in Medicine
  • News Archives
  • About Us
    • Media Contact
    • Share Your News
    • News Feeds
    • Social Media
    • Contact Us
Home » Toxicity Finding Promotes Cautious Approach for Drug Class
Disease Discoveries

Toxicity Finding Promotes Cautious Approach for Drug Class

By Roger AndersonJun 6, 2014
Share
Facebook Twitter Email
Puneet Opal, MD, PhD, associate professor of Neurology and Cell and Molecular Biology, studies spinocerebellar ataxia type 1, a neurodegenerative disease that affects an estimated 50,000 people.

New Northwestern Medicine research is offering a cautionary note regarding the use of histone deacetylase inhibitors (HDIs) to treat cancer, neurodegeneration and a host of other diseases.

HDIs inhibit the expression of enzymes called histone deacetylases (HDACs).  A number of studies suggest that HDACs – in particular HDAC3 – play a role in causing neurodegeneration.

Puneet Opal, MD, PhD ’95, associate professor of Neurology and Cell and Molecular Biology, used a genetic approach to explore the potential therapeutic benefits of reducing the enzyme. Opal studies spinocerebellar ataxia type 1 (SCA1), a neurodegenerative disease that causes a host of movement issues.

SCA1 shares many neurodegenerative traits with several other diseases of the brain, the most well-known of which is Huntington’s, where HDAC inhibitors have also been proposed as promising therapeutic agents.

“We were surprised to find that deleting one of the two copies of the HDAC3 gene had no effect on the disease,” said Dr. Opal, a member of the Center for Genetic Medicine and Parkinson’s Disease and Movement Disorders Center, where he directs the Ataxia Clinic. “But when we completely eliminated HDAC3 from Purkinje cells (neurons) in the cerebellum, the result was equivalent to an enhanced disease state.”

The findings were recently published in Human Molecular Genetics.

“The toxic effect on the nervous system caused by removing too much HDAC3 hasn’t been reported before,” Dr. Opal said. “These drugs are already being used to treat some neurological cancers, and our findings show the need to be extremely careful with the dosage.”

Scientists concluded that different dosing strategies or the combination of HDIs with other agents may help prevent the neuronal side effects of this still-promising class of drugs, though exact measures still need to be determined.

Dr. Opal’s research was supported by the National Institutes of Health grants R01 NS062051 and 1R01NS082351, with additional funding from the National Ataxia Foundation and the Brain Research Foundation.

Cancer Cell and Developmental Biology Genetics Neurology and Neuroscience Research
Share. Facebook Twitter Email

Related Posts

Genetic Variations Influence Drug Metabolism in Patients of African Descent

Feb 7, 2023

Potential Therapeutic Target for Schizophrenia Identified 

Feb 6, 2023

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Comments are closed.

Latest News

Workshop Teaches Medical Students Diagnosis Skills in Dermatology

Feb 7, 2023

Genetic Variations Influence Drug Metabolism in Patients of African Descent

Feb 7, 2023

Potential Therapeutic Target for Schizophrenia Identified 

Feb 6, 2023

Longtime Alcohol Consumption Speeds Up Biological Aging 

Feb 3, 2023

Grant Provides Imaging Technology to Department of Ophthalmology

Feb 2, 2023
  • News Center Home
  • Categories
  • Press Release
  • Media Coverage
  • Editor’s Picks
  • News Archives
  • About Us
Flickr Photos
Feinberg_In_Vivo_20221209_tcrawford-24
Feinberg_In_Vivo_20221209_tcrawford-16
Feinberg_In_Vivo_20221209_tcrawford-14
Feinberg_In_Vivo_20221209_tcrawford-5
Feinberg_In_Vivo_20221209_tcrawford-6
Feinberg_In_Vivo_20221209_tcrawford-10
Feinberg_In_Vivo_20221209_tcrawford-8
Feinberg_In_Vivo_20221209_tcrawford-18
Feinberg_In_Vivo_20221209_tcrawford
Feinberg_In_Vivo_20221209_tcrawford-23
Feinberg_In_Vivo_20221209_tcrawford-25
Feinberg_In_Vivo_20221209_tcrawford-26

Northwestern University logo

Northwestern University Feinberg School of Medicine

RSS Facebook Twitter LinkedIn Flickr YouTube Instagram
Copyright © 2023 Northwestern University
  • Contact Northwestern University
  • Disclaimer
  • Campus Emergency Information
  • Policy Statements

Type above and press Enter to search. Press Esc to cancel.